News

Drug discovery centres join forces
Enlarge image

ResearchUKBelgiumGermany

Drug discovery centres join forces

22.01.2013 - Four European top-notch translational health research centres have joined an alliance to accelerate global drug development.

The Global Alliance of Leading Drug Discovery and Development Centres, which pools the expertise of renowned drug development service centres, has the ambitious goal to ultimately improve the rate at which academic research is translated into new medicines. However, the centres are no white spots on the map: the founding organisations include the Canadian Centre for Drug Research and Development (CDRD); the Lead Discovery Center (LDC), Germany; the Scripps Research Institute, La Jolla (US); the Centre for Drug Design and Discovery (CD3), KU Leuven, Belgium; as well as UK-based MRC Technology and Cancer Research Technology.  

Dr. Bert Klebl, Managing Director and Chief Scientific Officer of the Lead Discovery Centre stressed, “By joining forces and sharing complementary expertise and infrastructure, we will be even more effective in closing the gap between basic research and industry to the benefit of patients.” The centres said they represent close to 400 drug developers collaborating with tens of thousands of academic scientists around the globe on more than 165 therapeutic projects. The alliance wants to establish itself as partner for the biopharmaceutical industry.  

Under the terms of the collaboration agreement, member organisations will collaborate on mutually-beneficial projects, share best practices, expertise and resources, and develop common standards and performance measurements - ultimately working together to improve the conversion of global early-stage technology into much needed therapies. Karimah Es Sabar, President and CEO of CDRD commented, “We see a multitude of translational research initiatives around the world, but until now, these have for the most part, worked in isolation of one another. This Alliance will be a powerful vehicle in bringing such organisations together, leveraging one another's strengths, and ultimately making for a much more effective global translational research environment.”

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-01/drug-discovery-centres-join-forces.html

BusinessUK

20.08.2014 Biopharmaceutical contract manufacturer Fujifilm Diosynth Biotechnologies is expanding its cell culture manufacturing capacity further with a new 2,000l single-use bioreactor at the company’s site in Billingham, UK.

BusinessEUGermanyUK

15.08.2014 Some of Europe’s biggest pharma companies are competing in a bidding war for US biotech Intermune Inc., Bloomberg reports, citing insider reports as the source.

ResearchEUGermanyUK

13.08.2014 The Ebola epidemic is still raging on in West Africa and thus far there is

neither vaccine nor cure for the viral disease. The only flickers of hope:

an experimental antibody serum and an early-stage vaccine.

BusinessFrance

11.08.2014 Will Sanofi succeed where Pfizer failed? The French pharmaceutical company has taken on the commercialisation of Mannkind Corporation’s inhaled insulin product Afrezza.

ResearchSwedenGermany

08.08.2014 Boehringer Ingelheim is walking away from Swedish Orexo's prostaglandin inhibition project OX-MPI. Germany's largest researching pharmaceutical company had been responsible for the project's research and development since 2005.

ResearchSwitzerlandDenmark

06.08.2014 Roche is re-expanding its involvement in RNAi technologies. The Swiss pharmaceutical company will pay up to €335m for the acquisition of the Danish company Santaris Pharma A/S.

ResearchUKSwitzerland

03.08.2014 In its efforts to become the leading country in genetic research, the UK has attracted investments worth more than £300m (€376m) to map 100,000 human genomes by 2017.

BusinessSpainUKSweden

31.07.2014 Astrazeneca is buying the rights to Almirall’s respiratory drugs in a deal worth up to €1.56bn.

BusinessFranceGermanySwitzerlandUK

30.07.2014 Rumours have it that French Danone wants to sell its medical nutrition business to US drugmaker Hospira for US$5bn in yet another tax inversion deal.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • SANTHERA74.95 CHF10.30%
  • BIOTEST80.50 EUR6.83%
  • WILEX2.22 EUR5.71%

FLOP

  • 4SC1.20 EUR-6.25%
  • VITA 343.78 EUR-2.83%
  • EPIGENOMICS3.12 EUR-2.50%

TOP

  • MAGFORCE6.50 EUR20.4%
  • LONZA101.10 CHF9.2%
  • SANTHERA74.95 CHF7.8%

FLOP

  • WILEX2.22 EUR-32.3%
  • VITA 343.78 EUR-20.1%
  • MOLOGEN7.80 EUR-17.5%

TOP

  • SANTHERA74.95 CHF3556.1%
  • CO.DON2.50 EUR228.9%
  • PAION2.40 EUR185.7%

FLOP

  • CYTOS0.27 CHF-93.3%
  • MEDIGENE4.60 EUR-66.4%
  • THERAMETRICS0.08 CHF-46.7%

No liability assumed, Date: 20.08.2014